Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors.

Wiete Kromdijk,Alwin D. R. Huitema,M. E. Kemper,J. H. M. Schellens,D.J. Richel,Heinz-Josef Klümpen

Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors.

2010

Wiete Kromdijk
Alwin D. R. Huitema
M. E. Kemper
J. H. M. Schellens
D.J. Richel
Heinz-Josef Klümpen

2572 Background: Temsirolimus (CCI-779, TEM) is a selective inhibitor of mTOR with anticancer activity in a limited number of cancer types. A potential mechanism of drug resistance of TEM is feedba...

Keywords:

Cancer research
Pathology
Nelfinavir
Temsirolimus
Medicine
Pharmacokinetics
potential mechanism
in patient
Oncology
Drug resistance
Cancer
Internal medicine
PI3K/AKT/mTOR pathway

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations